109 related articles for article (PubMed ID: 28550387)
1. Correlation of c-MET Expression with PD-L1 Expression in Metastatic Clear Cell Renal Cell Carcinoma Treated by Sunitinib First-Line Therapy.
Kammerer-Jacquet SF; Medane S; Bensalah K; Bernhard JC; Yacoub M; Dupuis F; Ravaud A; Verhoest G; Mathieu R; Peyronnet B; Brunot A; Laguerre B; Lespagnol A; Mosser J; Dugay F; Belaud-Rotureau MA; Rioux-Leclercq N
Target Oncol; 2017 Aug; 12(4):487-494. PubMed ID: 28550387
[TBL] [Abstract][Full Text] [Related]
2. Long-term efficacy of crizotinib in a metastatic papillary renal carcinoma with MET amplification: a case report and literature review.
Rochigneux P; Thomassin-Piana J; Laibe S; Brunelle S; Salem N; Escudier B; Vassal G; Gravis G
BMC Cancer; 2018 Nov; 18(1):1159. PubMed ID: 30466410
[TBL] [Abstract][Full Text] [Related]
3. MET expression and copy number status in clear-cell renal cell carcinoma: prognostic value and potential predictive marker.
Macher-Goeppinger S; Keith M; Endris V; Penzel R; Tagscherer KE; Pahernik S; Hohenfellner M; Gardner H; Grüllich C; Schirmacher P; Roth W
Oncotarget; 2017 Jan; 8(1):1046-1057. PubMed ID: 27894094
[TBL] [Abstract][Full Text] [Related]
4. Unraveling the Significance of MET Focal Amplification in Lung Cancer: Integrative NGS, FISH, and IHC Investigation.
Xiang C; Lv X; Chen K; Guo L; Zhao R; Teng H; Ye M; Kuang T; Hou T; Liu C; Du H; Zhang Z; Han Y
Mod Pathol; 2024 Apr; 37(4):100451. PubMed ID: 38369190
[TBL] [Abstract][Full Text] [Related]
5. Impact of sunitinib resistance on clear cell renal cell carcinoma therapeutic sensitivity
Ghosh S; Garige M; Haggerty PR; Norris A; Chou CK; Wu WW; Shen RF; Sourbier C
Cell Cycle; 2024 Jan; 23(1):43-55. PubMed ID: 38263737
[TBL] [Abstract][Full Text] [Related]
6. Genomic Analysis Reveals Novel Specific Metastatic Mutations in Chinese Clear Cell Renal Cell Carcinoma.
Meng H; Jiang X; Cui J; Yin G; Shi B; Liu Q; Xuan H; Wang Y
Biomed Res Int; 2020; 2020():2495157. PubMed ID: 33062672
[TBL] [Abstract][Full Text] [Related]
7. PD-L1 expression and its prognostic value in metastatic papillary renal cell carcinoma: Results from a GETUG multicenter retrospective cohort.
Naffrichoux J; Poupin P; Pouillot W; Linassier C; Rioux-Leclercq N; De Vries-Brilland M; Mourey L; Laguerre B; Oudard S; Gross-Goupil M; Mousset C; Gravis G; Rolland F; Moise L; Emambux S; Vassal C; Zanetta S; Penel N; Albiges L; Fromont G; Cancel M
Eur J Cancer; 2024 May; 205():114121. PubMed ID: 38749111
[TBL] [Abstract][Full Text] [Related]
8. Mutation Profile Variability in the Primary Tumor and Multiple Pulmonary Metastases of Clear Cell Renal Cell Carcinoma. A Review of the Literature and Analysis of Four Metastatic Cases.
Prochazkova K; Ptakova N; Alaghehbandan R; Williamson SR; Vaněček T; Vodicka J; Treska V; Rogala J; Pivovarcikova K; Michalova K; Slisarenko M; Hora M; Michal M; Hes O
Cancers (Basel); 2021 Nov; 13(23):. PubMed ID: 34885018
[TBL] [Abstract][Full Text] [Related]
9. Impressive and Prolonged Response with Lenvatinib in a Highly Pretreated Patient with Metastatic Clear Cell Renal Cancer: A Case Report.
Demurtas S; Frascaroli M; Sottotetti F; Rametta A; Procopio G; Locati LD
J Kidney Cancer VHL; 2024; 11(2):1-6. PubMed ID: 38628557
[TBL] [Abstract][Full Text] [Related]
10. PD-L1 and c-MET expression and survival in patients with small cell lung cancer.
Miao L; Lu Y; Xu Y; Zhang G; Huang Z; Gong L; Fan Y
Oncotarget; 2017 Aug; 8(33):53978-53988. PubMed ID: 28903317
[TBL] [Abstract][Full Text] [Related]
11. Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer.
Iacovelli R; Cossu Rocca M; Galli L; De Giorgi U; Sabbatini R; Santoni M; Mosca A; Fornarini G; Massari F; Masini C; Bersanelli M; Biasco E; Lolli C; Guida A; Berardi R; Terrone C; Pastorino A; Ardizzoni A; Pinto C; Buti S; Nolè F; Tortora G
Urol Oncol; 2017 Sep; 35(9):541.e7-541.e13. PubMed ID: 28572027
[TBL] [Abstract][Full Text] [Related]
12. Differential expression of c-Met between primary and metastatic sites in clear-cell renal cell carcinoma and its association with PD-L1 expression.
Lalani AA; Gray KP; Albiges L; Callea M; Pignon JC; Pal S; Gupta M; Bhatt RS; McDermott DF; Atkins MB; Woude GFV; Harshman LC; Choueiri TK; Signoretti S
Oncotarget; 2017 Nov; 8(61):103428-103436. PubMed ID: 29262573
[TBL] [Abstract][Full Text] [Related]
13. Current management of metastatic renal cell carcinoma: evolving new therapies.
Kumar R; Kapoor A
Curr Opin Support Palliat Care; 2017 Sep; 11(3):231-237. PubMed ID: 28590313
[TBL] [Abstract][Full Text] [Related]
14. Real-life patterns of use, safety and effectiveness of sunitinib in first-line therapy of metastatic renal cell carcinoma: the SANTORIN cohort study.
Noize P; Grelaud A; Bay JO; Chevreau C; Gross-Goupil M; Culine S; Ferrière JM; Moulin F; Robinson P; Balestra A; Lamarque S; Bernard MA; Lassalle R; Rouyer M; Droz-Perroteau C; Moore N; Fourrier-Réglat A; Ravaud A
Pharmacoepidemiol Drug Saf; 2017 Dec; 26(12):1561-1569. PubMed ID: 28573786
[TBL] [Abstract][Full Text] [Related]
15. Cabozantinib for the treatment of kidney cancer.
Abdelaziz A; Vaishampayan U
Expert Rev Anticancer Ther; 2017 Jul; 17(7):577-584. PubMed ID: 28633552
[TBL] [Abstract][Full Text] [Related]
16. Advances in small molecule therapy for treating metastatic thyroid cancer.
Krajewska J; Gawlik T; Jarzab B
Expert Opin Pharmacother; 2017 Aug; 18(11):1049-1060. PubMed ID: 28602103
[TBL] [Abstract][Full Text] [Related]
17. Integrating Immunotherapy Into the Management of Renal Cell Carcinoma.
Zibelman M; Plimack ER
J Natl Compr Canc Netw; 2017 Jun; 15(6):841-847. PubMed ID: 28596263
[TBL] [Abstract][Full Text] [Related]
18. Population Modeling Integrating Pharmacokinetics, Pharmacodynamics, Pharmacogenetics, and Clinical Outcome in Patients With Sunitinib-Treated Cancer.
Diekstra MH; Fritsch A; Kanefendt F; Swen JJ; Moes D; Sörgel F; Kinzig M; Stelzer C; Schindele D; Gauler T; Hauser S; Houtsma D; Roessler M; Moritz B; Mross K; Bergmann L; Oosterwijk E; Kiemeney LA; Guchelaar HJ; Jaehde U
CPT Pharmacometrics Syst Pharmacol; 2017 Sep; 6(9):604-613. PubMed ID: 28571114
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of pazopanib versus sunitinib for metastatic renal cell carcinoma in the United Kingdom.
Amdahl J; Diaz J; Sharma A; Park J; Chandiwana D; Delea TE
PLoS One; 2017; 12(6):e0175920. PubMed ID: 28636648
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
